HP Names Bruce Broussard Interim CEO As Enrique Lores Steps Down; Reaffirms Q1, FY26 Outlook

HP appointed Bruce Broussard, a board member since 2021 and former Humana CEO, as Interim CEO after Enrique Lores stepped down, while the board has engaged a global search firm to find a permanent replacement. The company reaffirmed its prior Nov. 25, 2025 outlook: Q1 FY2026 EPS $0.58–$0.66 (adjusted $0.73–$0.81) and full-year FY2026 EPS $2.47–$2.77 (adjusted $2.90–$3.20). Shares traded down about 2.02% pre-market at $19.40, reflecting investor caution over the sudden leadership change despite unchanged guidance.

Analysis

Market structure: A sudden CEO change with guidance reaffirmed benefits activists/private‑equity and cost‑focused managers who can push for buybacks/divestitures; near‑term winners include suppliers with high recurring consumables (stability) while premium PC peers (e.g., DELL) could gain share if execution slips. Reaffirmed FY26 adj EPS midpoint ~$3.05 implies HPQ trading at ~6.4x forward —signals a low‑growth/low‑multiple market pricing rather than a demand collapse; the modest ~2% pre‑market drop to $19.40 reflects uncertainty, not fundamentals.

Risk assessment: Tail risks include (1) activist/strategic break‑up or large dividend that re-rates equity positively, (2) a botched CEO transition causing margin deterioration or supplier disruptions, or (3) credit spread widening of 20–50 bps if investor confidence erodes —each low probability but >$1/share EPS impact possible. Immediate (days) = elevated volatility around management commentary; short (1–3 months) = CEO search developments; long (4+ quarters) = strategic moves (M&A, asset sales) that change cash flow profile. Hidden dependency: interim CEO from healthcare (Bruce Broussard) may emphasize operational KPIs over R&D, producing short‑term margin lift but long‑term product stagnation.

Trade implications: Direct play — consider establishing a 2–3% long position in HPQ at market (~$19.4) with a hard stop at 12% (~$17.07), and scale to 4–5% if price drops below $18.00; rationale: 6.4x FY26 adj EPS vs. peers. Options — sell cash‑secured $17.50 Apr puts (target premium ~$0.40–0.80) to collect yield and/or buy 3‑month $18 calls (time decay funded by selling a nearer‑dated put) to play a relief rally if CEO search signals continuity. Pair trade — long HPQ / short DELL equal dollar for 3–6 months to isolate HP‑specific governance risk.

Contrarian angles: Consensus underestimates the chance management change catalyzes a value‑realizing action (break‑up/buyback) within 6–12 months; the market may be overpricing governance risk given reaffirmed guidance. Conversely, don’t dismiss the risk that operational de‑prioritization of R&D could shave 5–10% off long‑term top line over 2–3 years —structural risk that argues for size limits and defined stops rather than a buy‑and‑hold conviction.

Key Decisions for Investors

• Establish a 2–3% long position in HPQ (ticker: HPQ) at current levels (~$19.40); set stop‑loss at 12% below entry (~$17.07) and scale to 4–5% if price falls below $18.00 within 30 trading days.
• Sell cash‑secured $17.50 Apr (60–90 day) puts on HPQ to generate yield and possibly acquire shares; target net put premium >= $0.40 (implying effective entry <= $17.10) and close if implied volatility contracts >40% from trade entry.
• Enter a pair trade: long HPQ / short DELL (equal dollar exposure) for 3–6 months to isolate HP governance risk; cut the pair if HPQ outperforms by >15% or if a CEO successor with clear tech hardware experience is announced.
• Monitor HP credit spreads and CDS: if IG spread widens >25 bps from current levels, reduce equity exposure by 50% and consider short HPQ calls or hedging via index‑put protection (60–90 day) to guard against contagion.